Researchers at Harvard University have demonstrated that a nonsurgical injection of programmable biomaterial can assemble in vivo into a 3-D structure to attack cancer cells and help to prevent other infectious diseases such as HIV.
Shire, settling into life on its own after a failed merger with AbbVie, believes its in-development drugs can bring in a combined $3 billion in sales by 2020, sharpening its focus on rare diseases and keeping an eye out for bolt-on acquisitions.
After three years of declining returns on R&D spend, the 12 largest operations have finally achieved an uptick in what they receive for each dollar of outlay. But the result is more of a bottoming out than a major turnaround, with returns still well below levels seen in 2010 and at least one company posting a negative yield.
Angiochem pulled off the rare feat of getting an anticancer antibody through the brain's protective mesh in a preclinical study, and now the Canadian biotech is on the hunt for partners to take the next step.
Scientists have developed a high-data-rate, low-power wireless brain sensor and published testing data on it in the latest issue of the journal Neuron. The researchers expect that these sensors could lead to new and unique patient data collection since subjects needn't remain tethered by cables.
Pfizer is the latest pharma heavyweight to get behind the promise of gene therapy, as the New York drugmaker has laid out plans to set up a dedicated R&D operation and signed a deal with startup Spark Therapeutics to kick-start the effort.
A new cancer treatment from Novartis and its partners at the University of Pennsylvania came through in another round of early studies, posting stellar results and burnishing the promise of therapies that train the immune system to bear down on tumor cells.
Just a few months after Agios Pharmaceuticals highlighted clear indications of success for its early-stage drug AG-221 for various blood cancers, the biotech has followed up with a bonus round of promising results at the annual scientific meeting of the American Society of Hematology.
Merck's new PD-1 cancer drug Keytruda (pembrolizumab) has posted another round of positive early-stage results that help demonstrate its potential in an important cancer R&D arena: hematology. But some of the biggest players and punters in the immuno-oncology field may be left wondering if Merck's top therapeutic hopeful is losing market ground to Bristol-Myers Squibb's rival treatment.
India should take a cue from the biotech hotbeds of the U.S. and U.K., a local trade groups says, investing in infrastructure to help foster startups and grow innovation clusters of its own.